drugset
drugset / Trial / NCT04417192

Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer

NCT04417192 ↗

Phase 2 Completed 30 enrolled National Cancer Center Hospital East Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of preoperative olaparib monotherapy and preoperative olaparib plus pembrolizumab combination therapy in patients with untreated stage III, IV high-grade serous or Grade 3 endometrioid ovarian cancer with Homologous Recombination Deficiency (HRD) positivity.

Timeline

Start
2020-12-01
Primary completion
2023-06-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule 300 mg Oral
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

ovarian cancer